Sacubitril/valsartan in cardiovascular disease: evidence to date and place in therapy.

ABSTRACT: Cardiovascular (CV) disease is a major cause of morbidity and mortality in the developing and the developed world. Mortality from CV disease had plateaued in the recent years raising concerning alarms about the sustained efficacy of available preventive and treatment options. Heart failure (HF) is among the major contributors to the CV-related health care burden, a persisting concern despite the use of clinically proven guideline-directed therapies. A requirement for more efficient medical therapies coupled with recent advances in bio-innovation led to the creation of sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), which demonstrated substantial CV benefit when compared with the standard of care, enalapril, in patients with HF and reduced ejection fraction. Furth

SUBMITTER: Yandrapalli S 

PROVIDER: S-EPMC6041873 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature